Derman S G, Peralta L M
Department of Obstetrics and Gynecology, University of Maryland School of Medicine, Baltimore 21201, USA.
J Adolesc Health. 1995 Jan;16(1):6-11. doi: 10.1016/1054-139X(94)00055-J.
This article reviews information on currently available postcoital contraceptives, and discusses recent advances in postcoital contraception, mostly notably RU 486.
Postcoital contraceptives, or "morning after pills," are currently available in the form of high dose estrogens, oral contraceptives, danazol and intrauterine devices. These methods are plagued by high incidences of side effects and less than optimal success rates.
Currently, their primary use in the adolescent age group is for victims of sexual assault, but they may also be used as back-up for consensual unprotected intercourse. RU 486, best known as a first trimester abortifacient, has a number of potential uses, including that of a postcoital contraceptive. Two recently published studies from the UK showed RU 486 to have a very low pregnancy rate and fewer side effects when compared with current methods. RU 486 may someday replace high doses of oral contraceptives as the method of choice for postcoital contraception.
本文回顾了目前可用的性交后避孕药的相关信息,并讨论了性交后避孕的最新进展,最显著的是RU 486。
性交后避孕药,即“紧急避孕药”,目前有高剂量雌激素、口服避孕药、达那唑和宫内节育器等形式。这些方法存在副作用发生率高和成功率不尽人意的问题。
目前,它们在青少年年龄组中的主要用途是为性侵犯受害者提供避孕,但也可用于双方自愿的无保护性交后的备用避孕。RU 486最为人所知的用途是作为孕早期堕胎药,它还有许多潜在用途,包括作为性交后避孕药。英国最近发表的两项研究表明,与目前的方法相比,RU 486的妊娠率非常低,副作用也更少。RU 486可能有一天会取代高剂量口服避孕药,成为性交后避孕的首选方法。